News

  • 9 June 2014

    Merck to acquire Idenix Pharmaceuticals for $3.8bn

    Merck has reached a definitive agreement worth $3.85bn to acquire Idenix Pharmaceuticals, a biopharmaceutical firm specialising in the discovery and development of drugs for treating human viral diseases.

Close
Close
Close

Go Top